Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 527 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: INTENSITY MODULATED RADIOTHERAPY Clear all
Terminated Not applicable Interventional

Adjuvant Radiation for High Risk Bladder Cancer

NCT01954173
View directory record Official record
Conditions
Bladder Cancer, Squamous Cell Carcinoma of the Bladder, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Interventions
3D conformal radiation therapy
Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Nov 13, 2026, 9:52 AM EST
Active, not recruiting Phase 1 Interventional

NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer

NCT06459869
View directory record Official record
Conditions
Locally Advanced Rectal Cancer (LARC)
Interventions
NG-350A IV administration, Capecitabine oral administration, Radiotherapy
Drug · Radiation
Lead sponsor
Akamis Bio
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Orlando, Florida • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 13, 2026, 9:52 AM EST
Completed Phase 2 Interventional Results available

Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer

NCT00387127
View directory record Official record
Conditions
Neoplasms, Head and Neck
Interventions
Lapatinib oral tablets, radiotherapy, cisplatin chemotherapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
3
States / cities
Minneapolis, Minnesota • Kansas City, Missouri • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Nov 13, 2026, 9:52 AM EST
Completed Phase 1Phase 2 Interventional Results available

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

NCT04037254
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Gonadotrophin Releasing Hormone, Intensity-Modulated Radiation Therapy, Niraparib
Biological · Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
94
States / cities
Gilbert, Arizona • Tucson, Arizona • Duarte, California + 77 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 13, 2026, 9:52 AM EST
Recruiting Not applicable Interventional

Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer

NCT04567771
View directory record Official record
Conditions
Cervical Carcinoma, Endometrial Carcinoma, Endometriosis, Pelvic Inflammatory Disease
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 13, 2026, 9:52 AM EST
Completed Phase 1 Interventional

Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer

NCT00911118
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma
Interventions
Hypofractionated, image-guided, intensity-modulated external beam radiation
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
7
States / cities
Commack, New York • Harrison, New York • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Nov 13, 2026, 9:52 AM EST
Recruiting No phase listed Observational

De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx

NCT05600842
View directory record Official record
Conditions
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Intensity-Modulated Radiation Therapy (IMRT)
Radiation
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Nov 13, 2026, 9:52 AM EST
Completed Not applicable Interventional Results available

Study of Prone Accelerated Breast And Nodal IMRT

NCT02308488
View directory record Official record
Conditions
Lymphedema
Interventions
Intensity-modulated radiation therapy (IMRT)
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
36 Years to 90 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Nov 13, 2026, 9:52 AM EST
Recruiting Phase 2 Interventional

Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy

NCT06477692
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
ENI using IMRT with or without chemotherapy, INRT, ENI
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Nov 13, 2026, 9:52 AM EST
Completed Not applicable Interventional Results available

Feasibility of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer

NCT01576939
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Intensity Modulated Radiation Therapy
Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Nov 13, 2026, 9:52 AM EST
Completed Phase 1 Interventional

Using Intensity Modulated Radiation Therapy (IMRT) for Brain Metastases

NCT00328575
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
Intensity-Modulated Radiotherapy (IMRT)
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Nov 13, 2026, 9:52 AM EST
Terminated Phase 1 Interventional

Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT01912625
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
3-Dimensional Conformal Radiation Therapy, Carboplatin, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Trametinib
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
5
States / cities
Rochester, Minnesota • Cleveland, Ohio • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Nov 13, 2026, 9:52 AM EST
Active, not recruiting Phase 1 Interventional

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

NCT04533750
View directory record Official record
Conditions
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oral Cavity Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Intensity-Modulated Radiation Therapy, Peposertib
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
27
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 13, 2026, 9:52 AM EST
Terminated Not applicable Interventional Results available

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer

NCT01367301
View directory record Official record
Conditions
Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma, Stage IIB Uterine Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Carcinosarcoma
Interventions
paclitaxel, carboplatin, external beam radiation therapy, brachytherapy, intensity-modulated radiation therapy, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Nov 13, 2026, 9:52 AM EST
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

NCT00936390
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
499
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 353 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Nov 13, 2026, 9:52 AM EST
Completed Phase 2 Interventional Results available

Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer

NCT01005329
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions
Bevacizumab, Carboplatin, Cisplatin, Intensity-Modulated Radiation Therapy, Paclitaxel
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
38
States / cities
Berkeley, California • Walnut Creek, California • Colorado Springs, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Nov 13, 2026, 9:52 AM EST
Active, not recruiting Phase 2 Interventional

Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma

NCT00715611
View directory record Official record
Conditions
Mesothelioma
Interventions
Pleurectomy/Decortication, pemetrexed and cisplatin or carboplatin, Intensity Modulated Radiation Therapy
Procedure · Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
12
States / cities
Tampa, Florida • Boston, Massachusetts • Rochester, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 13, 2026, 9:52 AM EST
Completed Phase 1Phase 2 Interventional Results available

Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer

NCT00851877
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Cetuximab, Cisplatin, Nab-Paclitaxel, intensity-modulated radiation therapy
Biological · Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Nov 13, 2026, 9:52 AM EST
Recruiting Phase 1Phase 2 Interventional

Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma

NCT06327477
View directory record Official record
Conditions
Retroperitoneal Sarcoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Intensity-Modulated Radiation Therapy, Resection, Spatially-fractionated Radiation Therapy
Procedure · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Nov 13, 2026, 9:52 AM EST
Terminated Phase 2 Interventional Results available

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

NCT03840902
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
M7824, Placebo, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin, Intensity Modulated Radiation Therapy (IMRT)
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
21
States / cities
Orange, California • Santa Monica, California • Colorado Springs, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Nov 13, 2026, 9:52 AM EST
Completed Phase 1 Interventional

Intensity Modulated Radiotherapy for Breast Cancer

NCT00594477
View directory record Official record
Conditions
Breast Cancer
Interventions
IMRT
Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Nov 13, 2026, 9:52 AM EST
Terminated Phase 2 Interventional Results available

Partial Breast Irradiation Using Accelerated Intensity Modulated Radiotherapy

NCT00581529
View directory record Official record
Conditions
Breast Cancer
Interventions
IMRT
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
40 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Nov 13, 2026, 9:52 AM EST
Recruiting Phase 2 Interventional

Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

NCT04992780
View directory record Official record
Conditions
Non Small Cell Lung Cancer Stage
Interventions
Hypo-Fractionation, Standard-Fractionation
Radiation
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Kansas City, Kansas • Overland Park, Kansas • Topeka, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Nov 13, 2026, 9:52 AM EST
Active, not recruiting Phase 1 Interventional

TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT

NCT04281199
View directory record Official record
Conditions
Acute Leukemia, Myelodysplastic Syndrome
Interventions
Hematopoietic Cell Transplantation, Intensity-Modulated Radiation Therapy, Tomotherapy, Total-Body Irradiation, Volume Modulated Arc Therapy
Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Nov 13, 2026, 9:52 AM EST